Search PubMedSearch

Biomedical subjects

P Kardos

Publications and source records attributed to P Kardos.

8 recordsLinked to original sources

[Chronic persistent cough in general practice: diagnosis and therapy in 329 patients over the course of 2 years].

Chronic Cough: Chronic persistent cough (CPC) lasting from several months to years - without radiographic or spirometric evidence of its cause - was a surprisingly frequent reason (5,7% of all new referrals) to consult our practice. Sophisticated diagnostic evaluation and therapeutic regimen are necessary. We performed a prospective study on 329 consecutive patients (106 male, 223 female) over a two-year period. 65% of the patients had cough as a consequence of bronchial hyperresponsiveness; 27% due to upper airways disease, i.e. often very common rhinitis or pharyngitis; 14% chronic bronchitis; 5% gastrooesophageal reflux (GER); 3% drug induced cough; 4% other causes. 10% of the patients discontinued the diagnostic evaluation prematurely. In 14% the cause for CPC remained unclear and no relief could be achieved. Furthermore, there is a need for consecutive studies to address the following questions: 1. The cause of the striking difference in gender (male : female = 1 : 2) remains unclear. 2. Wether a cough recorder - as occasionally reported in the literature - is needed for an objective evaluation of cough [9]. 3. A standardised methodology of 24 h pH monitoring for the diagnosis of CPC as a consequence of GER has yet to be established.

Adolescent

Dietary ellagic acid inhibits the enzymatic activity of CYP1A1 without altering hepatic concentrations of CYP1A1 or CYP1A1 mRNA.

The anticarcinogen ellagic acid significantly reduces the incidence of polycyclic aromatic hydrocarbon induced carcinomas, in association with significant reductions in benzo[a]pyrene hydroxylase activity and CO reducible hepatic cytochrome P450. This suggested that ellagic acid reduced hepatic concentrations of CYP1A1, but these changes occurred without any alteration in CYP1A1 mRNA or in immunoreactive CYP1A1. Dietary ellagic acid results in muMolar concentrations of ellagic acid in hepatic tissue. Addition of similar concentrations of ellagic acid in vitro directly inhibited the measurement of benzo[a]pyrene hydroxylase activity and CO reducible cytochrome P450. Thus dietary ellagic acid does not alter the hepatic concentration of CYP1A1, but the dietary ellagic acid remaining in hepatic tissue appears to directly inhibit the measurement of benzo[a]pyrene hydroxylase activity and CO reducible cytochrome P450.

Animals

[Salazosulfapyridine-induced eosinophilic pneumonia with pulmonary and cutaneous epithelioid cell granulomatosis in Sjögren syndrome].

A 68-year old woman suffering from Sjögren's syndrome for the last 30 years took sulphasalazine (SSP) for severe signs and symptoms at the joints. Soon after the start of this medication she developed progressive cough and shortness of breath. After two years she was referred for evaluation of a hemoptysis and a reddish skin lesion. The chest radiograph showed wide spread interstitial infiltrates in the lower lobes and some fibrotic changes. FVC was slightly reduced, DLCO markedly reduced. There was a high percentage of eosinophils in the bronchoalveolar lavage (55.2%). Transbronchial lung biopsy and skin biopsy demonstrated epitheloid granulomata. SSP was discontinued. After a short period of prednisone treatment the patient's condition improved considerably. After two months of followup neither pulmonary infiltrates nor any skin lesions were found. History and the clinical course after discontinuation of SSP indicate the relation of these infiltrates to SSP treatment. The previously published case reports of SSP-related lung disorders are reviewed. Three of these case reports included bronchoalveolar lavage. Our data suggest that patients with SSP related pulmonary infiltrates may have a marked increase of eosinophils in the bronchoalveolar lavage fluid.

Aged

Growth hormone-releasing factor releases ACTH from an AtT-20 mouse pituitary tumor cell line but not from normal pituitary cells.

Corticotropin-releasing factor (CRF) and both human pancreatic growth hormone-releasing factor (hp-GRF) and rat hypothalamic GRF (rh-GRF) stimulated ACTH release from neoplastic AtT-20 mouse pituitary tumor cells in a dose-dependent fashion, with CRF inducing a 10-fold increase and GRF a maximal increment of approximately one-half that of CRF. Neither rh-GRF nor hp-GRF induced ACTH release in normal anterior pituitary cells. Pretreatment with either dexamethasone or somatostatin prior to the addition of rh-GRF inhibited the increase in ACTH release. Both ovine CRF and rh-GRF stimulated adenosine 3,5-monophosphate production in AtT-20 cells. The weak but clearly discernible effect of GRF on ACTH release from AtT-20 cells may be due to an abnormality in the AtT-20 cell receptor.

Adrenocorticotropic Hormone

Corticotrophin-releasing factor in extra-hypothalamic brain of the mouse: demonstration by immunoassay and immunoneutralization of bioassayable activity.

Corticotrophin-releasing factor (CRF) bioactivity has been described in the extra-hypothalamic brain, but its relationship to hypothalamic CRF has remained questionable. Of the seven regions of the mouse brain examined, highest concentrations of CRF-like immunoreactivity (CRF-LI) and bioassayable CRF activity were present in the median eminence and hypothalamus. However, substantial CRF-LI and bioassayable CRF activity were also seen in brain extracts from the amygdala, thalamus, frontal cortex, pons medulla and cerebellum. Bioactivity was largely neutralized by prior incubation with heat-inactivated antiserum to ovine CRF. These findings, in conjunction with previous immunocytochemical evidence, strongly suggest that a substance closely resembling hypothalamic CRF is present in the extrahypothalamic brain of the mouse.

Amygdala

[Intermittent mandatory ventilation (IMV) -- a new method in the treatment of severe respiratory insufficiency (author's transl)].

The intermittent mandatory ventilation (IMV) is a new method of ventilatory support developed in the USA. It allows the patient to breathe spontaneously as desired and also delivers a mechanical hyperinflation at regular preset intervals. IMV is especially effective in cases of severe respiratory insufficiency after conservative management as well as assisted ventilation have failed and helps avoiding the disadvantages of controlled mechanical ventilation. IMV fully utilises and assists the existing though insufficient spontaneous respiration which is integrated into the total ventilation. Patient acceptance and cooperation has been excellent and their weaning from respirator has been facilitated by a gradual reduction of the hyperinflation. Two cases are reported to illustrate technical details and the practical use of the method followed by a discussion of its advantages and indication.

Evaluation Studies as Topic